alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit








Exhibit 10.2
	
					
	
	 
	 
	2101 North University Drive

	 
	 
	Fargo, ND 58102

	 
	 
	Phone: 701.297.3022

	 
	 
	Fax: 800.448.4889

	 
	 
	www.DMSHealthTechnologies.com






June 9, 2015


Philips Healthcare
3000 Minuteman Road MS 400
Andover, MA 01810
Facsimile: (855) 207-4468


Re:      Consolidated Agreements, dated April 1, 2014, between DMS Health Technologies, Inc. and Philips Healthcare (the "Agreements")


Reference is hereby made to the General Governing Terms Across Schedules A, B and C between DMS Health Technologies, Inc. ("DMS") and Philips Healthcare, a division of Philips Electronics North America  Corporation ("Philips"), which govern the Agreements (the "General Terms").


We  hereby notify you that the stockholders of Project Rendezvous Holding Corporation, the direct parent           corporation of DMS ("Parent"), are entering into a Stock Purchase Agreement, dated October 13, 2015, with Digirad Corporation ("Buyer"), pursuant to which Buyer will acquire all of the outstanding  shares of capital stock of Parent (the "Sale").


We acknowledge that Section 2.d.(iii) of the General Terms states that the party notified of a Change of Control (as defined in the General Terms) may terminate the Agreements immediately upon such Change of Control, and we understand that the Sale may be interpreted to constitute a Change of Control.












[Remainder of page intentionally left blank]














	
					
	
	 
	 
	2101 North University Drive

	 
	 
	Fargo, ND 58102

	 
	 
	Phone: 701.297.3022

	 
	 
	Fax: 800.448.4889

	 
	 
	www.DMSHealthTechnologies.com




        
Please sign where indicated below to indicate (i) your acknowledgement of, and consent to, the Sale, (ii) your waiver of any right of first refusal that you otherwise  may have in connection with the Sale under the terms  of the Agreements, and (iii) your agreement you will not exercise any right that you otherwise may have to  terminate  any of the Agreements solely as a result of the Sale constituting a Change of Control in exchange for an agreed upon modification of the termination for convenience clause from 180 days to 90 days prior written notice, and that the Agreements shall remain in full force and effect immediately following the Sale. Philips Comment: Philips  would be open to waiving its right to terminate the contract immediately upon 10 days post change of control in exchange of a termination for convenience provision modification of 180 days prior written notice to 90 days. This document seeks to alter our arrangement under the DMS contract and Philips is open to that based on the above.




DMS HEALTH TECHNOLOGIES, INC.





Accepted and agreed to:


PHILIPS HEALTHCARE, 
a division of Philips Electronics
North America Corporation
Exhibit 21
                             Subsidiaries
                                   
                         Polaroid Corporation
                     Year ended December 31, 1995


Name of Subsidiary                          Place of Incorporation
-------------------------------------------------------------------

Inner City, Inc.                                   Delaware
Polint, Inc.                                       Delaware
PMC, Inc.                                          Massachusetts
Polaroid Caribbean Corporation                     Delaware
Polaroid Asia Pacific International Inc.           Delaware
Polaroid Asia Pacific Limited                      Delaware
      Polaroid of Shanghai Limited                 China
Polaroid Europe Limited                            United Kingdom
Polaroid Foundation                                Delaware
Polaroid Canada Inc.                               Canada
Polaroid Gesellschaft mit beschrankter Haftung     Germany
Polaroid Australia Pty. Limited                    Australia
Polaroid Gesellschaft m.b.H.                       Austria
Polaroid Far East Limited                          Hong Kong
Nippon Polaroid Kabushiki Kaisha                   Japan
Polaroid (Norge) A/S                               Norway
Polaroid de Mexico S.A. de C.V.                    Mexico
Polaroid Aktiebolag                                Sweden
Polaroid A.G.                                      Switzerland
Polaroid (U.K.) Limited                            United Kingdom
Polaroid A/S                                       Denmark
Polaroid International B.V.                        Netherlands
      Polaroid (Italia) S.p.A.                     Italy
      Polaroid (France) S.A.                       France
      Polaroid (Belgium) N.V.                      Belgium
      Polaroid (Europa) B.V.                       Netherlands
      Polaroid Nederland B.V.                      Netherlands
      Svetozor                                     Russia
      Polaroid Graphics Imaging B.V.               Netherlands
Polaroid do Brasil Ltda.                           Brazil
Polaroid Singapore Private Limited                 Singapore
Polaroid Oy                                        Finland
Polaroid Espana, S.A.                              Spain
Polaroid Foreign Sales B.V.                        Netherlands
Polaroid India, Inc.                               Delaware
Polaroid Malaysia Limited                          Delaware
Polaroid India Private Limited                     India


Subsidiaries of subsidiary companies are indented and listed below
the respective companies through which they are controlled.
#### LOPEZ v. STATE.

No. 14282.

Court of Criminal Appeals of Texas.

April 22, 1931.

George P. Brown, of Edinburg, and L. J. Polk, o-f Pharr, for appellant.

Lloyd W. Davidson, State’s Atty., of Austin, for the State.

CALHOUN, J.

Offense, murder; penalty, ninety-nine years in the penitentiary.

The record is.before this court without either statement of facts or bills of exception, and nothing is presented for review.

The judgment is affirmed.

PER CURIAM.

The foregoing opinion of the Commission of Appeals has been examined by the judges of the Court of Criminal Appeals and approved by the court.
##### 



EXHIBIT 10.C.1
 
 Original Agreement
     Definitions
  Amendment to Section 8.5.
 Reports clause (ii)(B) Section 2.3 Section 2.4(a) Section 2.4(b)




---



##### 



Amendments to Exhibit I
  Daily Report Exhibit XII Section 8.5
  Loss Horizon Ratio
  Mid-Month Report Exhibit XI Section 8.5
  Representations and Warranties.
 Section 5.1
 - 2 -




---



##### 



Effectiveness ab initio
 Amendments and Waivers
 Counterparts
 Continuing Effect; No Other Amendments
 CHOICE OF LAW
 [SIGNATURE PAGES FOLLOW]
 - 3 -




---



##### 



SNG FUNDING COMPANY, L.L.C.By SNG Finance Company, L.L.C., its ManagerBy:
    
    /s/ John J. Hopper

Name: John J. HopperTitle: Vice PresidentSOUTHERN NATURAL GAS COMPANY, as ServicerBy:
    
    /s/ John . Hopper

Name: John J. HopperTitle: Vice PresidentBNP PARIBAS, acting through its New York Branch, as 
      Program Agent and as Managing Agent for the Starbird
      Investor GroupBy:
    
    /s/ Sean Reddington

Name: Sean ReddingtonTitle: Managing DirectorBy:
    
    /s/ Michael Gonik

Name: Michael GonikTitle: Director
 CONSENTED TO:STARBIRD FUNDING CORPORATION,as a Conduit PurchaserBy:
    
    /s/ Franklin P. Collazo

Name: Franklin P. CollazoTitle: Secretary
 [Signature pages to Amendment No. 1 to
SNG Receivables Purchase Agreement]




---



##### 



BNP PARIBAS, acting through its New York Branch,
      as Committed InvestorBy:
    
    /s/ Sean Reddington

Name: Sean ReddingtonTitle: Managing DirectorBy:
    
    /s/ Michael Gonik

Name: Michael GonikTitle: Director
 [Signature pages to Amendment No. 1 to
SNG Receivables Purchase Agreement]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                       8,581,380
<SECURITIES>                                         0
<RECEIVABLES>                               22,134,689
<ALLOWANCES>                                   895,980
<INVENTORY>                                          0
<CURRENT-ASSETS>                            33,469,172
<PP&E>                                      12,202,675
<DEPRECIATION>                               7,245,436
<TOTAL-ASSETS>                              60,116,357
<CURRENT-LIABILITIES>                       26,590,471
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        11,020
<OTHER-SE>                                  32,914,866
<TOTAL-LIABILITY-AND-EQUITY>                60,116,357
<SALES>                                              0
<TOTAL-REVENUES>                            44,095,412
<CGS>                                                0
<TOTAL-COSTS>                                4,615,638
<OTHER-EXPENSES>                            49,581,178
<LOSS-PROVISION>                               175,000
<INTEREST-EXPENSE>                         (1,439,435)
<INCOME-PRETAX>                            (8,836,969)
<INCOME-TAX>                                 2,392,984
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (11,229,953)
<EPS-PRIMARY>                                   (1.02)
<EPS-DILUTED>                                        0
        

</TABLE>
# C_2015245EN.01005101.xml

| 27.7.2015 | EN | Official Journal of the European Union | C 245/51 |
| --- | --- | --- | --- |

27.7.2015

EN

Official Journal of the European Union

C 245/51

---

Action brought on 15 May 2015 — ZZ v Council

(Case F-76/15)

(2015/C 245/64)

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: J.-N. Louis and N. de Montigny, lawyers)

Applicant:

Defendant: Council of the European Union

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision of the Brussels Settlements Office rejecting the application for extension of the recognition of the illness suffered by the applicant’s son as a serious illness and for the medical expenses connected therewith to be reimbursed at 100 %.

Form of order sought

Form of order sought

| — | Annul the decision of the Brussels Settlements Office of 8 April 2014 rejecting the application for extension of the recognition of the illness suffered by the applicant’s son as a serious illness and for the medical expenses connected therewith to be reimbursed at 100 %; |
| --- | --- |

—

Annul the decision of the Brussels Settlements Office of 8 April 2014 rejecting the application for extension of the recognition of the illness suffered by the applicant’s son as a serious illness and for the medical expenses connected therewith to be reimbursed at 100 %;

| — | Order the Council of the European Union to pay the costs. |
| --- | --- |

—

Order the Council of the European Union to pay the costs.

---
Materials Not Included in

Airworthiness Directive (AD) Docket

 Docket Number: FAA-2009-1249

 Directorate Identifier: 2009NM100AD

777-57A0064 IN 01 --- 5/28/09

777-57A0064 IN 02 --- 10/29/09

Name/Description of Item(s) Not Included in FDMS Docket and Maintained in the 

Supplemental AD Docket

MAY BE VIEWED AT: Federal Aviation Administration

Transport Airplane Directorate

Rules Docket

1601 Lind Ave. SW.,

Renton, WA 98057

425.227.1221

DURING THE HOURS OF: 9 a.m. and 3 p.m., Monday through Friday,

except Federal holidays.

Form Date: 03/05/2008
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Page 77872]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21739]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; Cystic Fibrosis Research 
and Translation Centers.
    Date: October 31-November 1, 2024.
    Time: 9:30 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, NIDDK, Democracy II, Suite 
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ryan G. Morris, Ph.D., Scientific Review 
Officer, National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, 6707 Democracy Boulevard, 
Rm 7015, Bethesda, MD 20892-2542, 301-594-4721, <a href="/cdn-cgi/l/email-protection#c0b2b9a1aeeeadafb2b2a9b380aea9a8eea7afb6"><span class="__cf_email__" data-cfemail="76040f1718581b1904041f0536181f1e58111900">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21739 Filed 9-23-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the November
28, 1998, financial statements and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          NOV-28-1998
<PERIOD-END>                               NOV-28-1998
<CASH>                                            1950
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     349452
<CURRENT-ASSETS>                                378272
<PP&E>                                          377868
<DEPRECIATION>                                 (32146)
<TOTAL-ASSETS>                                  748354
<CURRENT-LIABILITIES>                           182088
<BONDS>                                         336557
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           200
<OTHER-SE>                                      161233
<TOTAL-LIABILITY-AND-EQUITY>                    748354
<SALES>                                        1906862
<TOTAL-REVENUES>                               1909860
<CGS>                                          1420787
<TOTAL-COSTS>                                  1420787
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               37162
<INCOME-PRETAX>                                (35585)
<INCOME-TAX>                                   (13218)
<INCOME-CONTINUING>                            (22367)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (22367)
<EPS-PRIMARY>                                   (1.12)
<EPS-DILUTED>                                   (1.12)
        

</TABLE>
In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 20-967V

UNPUBLISHED

REGINA SALIOT, as Prochein Ami for

RICHARD SALIOT, Incapacitated 

Person,

 Petitioner,

v.

SECRETARY OF HEALTH AND 

HUMAN SERVICES,

 Respondent.

Chief Special Master Corcoran 

Filed: October 20, 2021

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession;

Table Injury; Influenza (Flu) Vaccine;

Guillain-Barre Syndrome (GBS)

Dennis W. Potts, Dennis W. Potts, Esq., Honolulu, HI, for Petitioner.

Kimberly Shubert Davey, U.S. Department of Justice, Washington, DC, for Respondent.

RULING ON ENTITLEMENT1

On August 4, 2020, Regina Saliot, on behalf of her husband, Richard Saliot, filed 

a petition for compensation under the National Vaccine Injury Compensation Program, 

42 U.S.C. §300aa-10, et seq.2(the “Vaccine Act”). Petitioner alleges that he suffered 

Guillan-Barré Syndrome (GBS) as a result of an influenza (flu) vaccination received on 

October 29, 2019 . Petition at 1. The case was assigned to the Special Processing Unit 

of the Office of Special Masters.

On October 8, 2021, Respondent filed his Rule 4(c) report in which he concedes

that Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 

1 Because this unpublished Ruling contains a reasoned explanation for the action in this case, I am required 

to post it on the United States Court of Federal Claims' website in accordance with the E-Government Act 

of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government 

Services). This means the Ruling will be available to anyone with access to the internet. In accordance 

with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, 

the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that 

the identified material fits within this definition, I will redact such material from public access. 

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease 

of citation, all section references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).
2

1. Specifically, “[I]t is [R]espondent’s position that “ [P]etitioner has satisfied the criteria 

set forth in the Vaccine Injury Table (“Table”) and the Qualifications and Aids to 

Interpretation (“QAI”). Id. at 9. Respondent further agrees that the scope of damages is 

limited to Petitioner’s GBS and its related sequelae only. Id. at 10.

In view of Respondent’s position and the evidence of record, I find that 

Petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Brian H. Corcoran

Brian H. Corcoran

Chief Special Master
Exhibit 32 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)   In connection with the Quarterly Report of Nurse Solutions, Inc., a Nevada corporation (the Company), on Form 10-Q for the quarter ending June 30, 2008, as filed with the Securities and Exchange Commission (the Report), I, Tomasz Zurawek, President/CEO/CFO of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to my knowledge:  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.    /s/ Tomasz Zurawek Tomasz Zurawek, President, CEO, CFO Dated:  July 24, 2008
RECORD OF

COMMUNICATION

TO:

File

SUBJECT

State concurrence with Prppo

(H PHONE CALL QOISCUSSION Q FIELD

D OTHER (SPECIFY!

(Rkcord of item checked •b

FROM:

Stephen A. Gilretn, Chief

ALNM Remedial Section

sed Remedy at Jacksonville and Re

TRIP QCONFEBENCE

ove)

DATE

9-24-90

TIME

3:00 EM

agers Road

Gary called in response to both a previous "letter (dated Sept. 18, 1990 )

and an earlier call in the day from Steve Gil rein to Mike Bates.

At issue was the use of a soil cap/cover and the use of a "warning grid "

between the waste and the fi11 . The State had earlier concurred with all

aspects of the remedy in a letter dated September 7 , 1990 , from Mike Bates

to Steve Veale with the exception of the cover issue. It was the

States' contention that a cap was not necessary and would hinder natural

degradation processes, especially ultra-violet light .

Subsequent to reviewing EPA' s rationale (See Sept. 18, 1990 letter) and

after a short discussion, Gary Martin said that the State would agree to

the use of a soil cover. Specifically, it was agreed that a warning

arid would not be utilized and that the soil fill would be referred to as

a soil "cover " not a soil "cap " in the ROD.

It was further stated that the EPA remedy would allow tor unrestricted

residential usage, as "iong as the integrity of the cover was kept intact.

Gary said that the enforceabitity of deed restrictions was currently being

reviewed by ADPC&E' s legal staff.

<N

in

v-i

CM

0

0

CONCLUSIONS, ACTION TAKEN OR REQUIRED

1 INFORMATION COPIES

TO:

EPA Farm 13004 (7-72) "IPLACC* CPA HQ FORM «100-< WHICH MAY •E uico UNTIL SUPPLY 11 CXHAUSTCO.

000955
EXHIBIT 32.1

THE PENN TRAFFIC COMPANY

CERTIFICATION PURSUANT TO  18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Penn Traffic Company (the "Company") on Form 10-K for the fiscal year ending February 2,
2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gregory J. Young, President & Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



|/s/GREGORY J. YOUNG                                    |  | 
|------------------------------------------------------ |  | 
|Gregory J. Young President and Chief Executive Officer |  | 

April 16,
2008

---



QuickLinks